OncoMatch/Clinical Trials/NCT06580002
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Is NCT06580002 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Riluzole for breast cancer.
Treatment: Riluzole — This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels of cancer survivors with cancer related cognitive impairment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Sarcoma
Gastric Cancer
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Prior therapy
Must have received: chemotherapy
Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions
Must have received: anthracycline-containing chemotherapy
Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
Must have received: platinum-based chemotherapy
Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years
Must have received: anticancer therapy
Non-breast cancer patients exposed to other anticancer therapies within the past 3 years
Lab requirements
Liver function
AST or ALT < 3x upper limit normal (ULN)
Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify